DBV Technologies (NASDAQ:DBVT) Now Covered by StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of DBV Technologies (NASDAQ:DBVT) in a report issued on Sunday. The firm set a “hold” rating on the stock.

Separately, HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of DBV Technologies in a research note on Wednesday, February 21st.

DBV Technologies Stock Down 1.1 %

Shares of NASDAQ DBVT opened at $0.68 on Friday. The business’s 50 day moving average is $0.77 and its two-hundred day moving average is $0.87. DBV Technologies has a 52-week low of $0.65 and a 52-week high of $2.37. The firm has a market cap of $131.54 million, a price-to-earnings ratio of -1.75 and a beta of 0.75.

DBV Technologies (NASDAQ:DBVT) last issued its quarterly earnings data on Thursday, March 7th. The company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.10. The business had revenue of $8.88 million during the quarter, compared to analysts’ expectations of $1.10 million. DBV Technologies had a negative return on equity of 46.33% and a negative net margin of 461.32%. During the same period in the previous year, the firm posted ($0.23) earnings per share. Analysts anticipate that DBV Technologies will post -0.88 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Cowen AND Company LLC purchased a new stake in shares of DBV Technologies during the 4th quarter worth approximately $49,000. Landscape Capital Management L.L.C. acquired a new stake in DBV Technologies during the 3rd quarter worth $94,000. Finally, Optiver Holding B.V. lifted its position in DBV Technologies by 595.2% in the third quarter. Optiver Holding B.V. now owns 274,874 shares of the company’s stock valued at $374,000 after acquiring an additional 235,337 shares during the last quarter. 71.74% of the stock is owned by institutional investors and hedge funds.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.